Approximately every fifth stroke in UK is due to AF and costs the UK National Health Service are between $12,000 and $17,500 per stroke. The aim of this study was to undertake a retrospective health economic analysis of the cost-effectiveness and implications related to opportunistic Atrial Fibrillation (AF) screening in primary care and the detection of previously undiagnosed AF cases in patients, and create a novel modelling solution that can empower individual users and organisations in England, Wales and Northern Ireland in their decision making, technology assessment, comparison of various anticoagulation drug groups cost effectiveness decisions

A model was built on Microsoft Excel suite and it combined advance Excel Functions Data with Visual Basic Macros with assumptions based on a feasibility study and a new patient pathway on which community pharmacist perform opportunistic AF checks using one lead mobile ECG device. Apart from Cost-Effectiveness, Return of investment and QALYS of the new pathway was also calculated. Finally, the model was tested using through a cost assessment scenario utilizing input data from various well-established sources:

• Background research into the NHS and NICE guideline content, current clinical practice, published information and available data.
• Gathering expert opinion.
• Testing the model, including the assumptions and outcomes.

Our results suggested that the opportunistic AF checks can be cost-effective for the NHS presenting a ROI of 60% and the model presents quick and accurate results without sacrificing customisation options.

CONCLUSIONS: this innovative modelling solution can provide policy makers with an accurate estimation of the costs related to AF incidences in various CCG population mixtures without sacrificing customisation options empowering users with the flexibility to adopt the model to their own variables findings and organisation.